All Eyes On Early Post-Shire Performance Ahead Of Takeda Q4
The first real indications of how Shire is contributing to Takeda will come when the Japanese firm issues its annual results next week, and investors will also be keeping a keen eye on the critical first forward guidance for the combined company.
You may also be interested in...
Takeda’s gut-selective biologic vedolizumab pushes ahead of other biologics in the race to make its mark in ulcerative colitis, a therapeutic sector targeted by numerous new investigational therapies.
Takeda saw continued growth for mainstay drugs in what it described as a ‘robust’ last quarter of reporting before the inclusion of Shire, with global blockbuster Entyvio leading the way, but gave away little new on widely anticipated post-deal divestments.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.